Denne siden fornyes snart!

Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: lørdag 20. oktober 
Største handler

13/11-2017 11:00:43: (NANO) Nordic Nanovector to Present at Jefferies Global Healthcare Conference

Oslo, Norway, 13th of November 2017

Nordic Nanovector ASA (OSE: NANO) announces that the company will be presenting
at the Jefferies Global Healthcare Conference on 15th of November 2017 in
London, UK.

The slides presented will be available on Nordic Nanovector's website
( in the investor and media section.

For further information, please contact:

IR enquiries:

Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76


Media enquiries:

Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson)

Tel: +44 207 638 9571


About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC)
designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly
develop Betalutin®, alone and in combination with other therapies, for the
treatment of major types of NHL, targeting first regulatory submission in
relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to
retain marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and
other immunotherapies for multiple cancer indications.

Further information about the Company can be found at

Forward-looking statements

This announcement may contain certain forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
Nordic Nanovector's business, financial condition and results of operations. The
terms "anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans", "should",
"projects", "will", "would" or, in each case, their negative, or other
variations or comparable terminology are used to identify forward-looking
statement. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in a forward
-looking statement or affect the extent to which a particular projection is
realised. Factors that could cause these differences include, but are not
limited to, implementation of Nordic Nanovector's strategy and its ability to
further grow, risks associated with the development and/or approval of Nordic
Nanovector's products candidates, ongoing clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology changes and new
products in Nordic Nanovector's potential market and industry, the ability to
develop new products and enhance existing products, the impact of competition,
changes in general economy and industry conditions and legislative, regulatory
and political factors. No assurance can be given that such expectations will
prove to have been correct. Nordic Nanovector disclaims any obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. This information is subject to a duty
of disclosure pursuant to Section 5-12 of the Securities Trading A

Ekstern link:

Nyheten er levert av OBI.

Utforming  |  Personvern  | Bytt til sanntid Ingen åpne markeder
lørdag 20/10-2018 00:28:29